Aiforia Technologies Plc, Company Release, Managers’ Transactions, July 24, 2026 at 11:00 a.m. EEST
Aiforia Technologies Plc – Managers’ Transactions – Jukka Tapaninen
____________________________________________
Person subject to the notification requirement
Name: Jukka Tapaninen
Position: Chief Executive Officer
Issuer: Aiforia Technologies Oyj
LEI: 743700TJRVBX7420Y723
Notification type: INITIAL NOTIFICATION
Reference number: 167288/6/6
____________________________________________
Transaction date: 2026-07-22
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000507934
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 2115 Unit price: 1.408 EUR
(2): Volume: 1572 Unit price: 1.41 EUR
Aggregated transactions (2):
Volume: 3687 Volume weighted average price: 1.40885 EUR
____________________________________________
Transaction date: 2026-07-23
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000507934
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 736 Unit price: 1.17 EUR
(2): Volume: 1198 Unit price: 1.198 EUR
(3): Volume: 1198 Unit price: 1.198 EUR
(4): Volume: 1181 Unit price: 1.198 EUR
Aggregated transactions (4):
Volume: 4313 Volume weighted average price: 1.19322 EUR
Further inquiries
Antti Ojala, CFO, Aiforia Technologies Plc,
tel. +358 40 7202448
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com